Drug · CHEMBL93
ZILEUTON
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ZILEUTON. Drugs and targets, record CHEMBL93. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL93
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Arachidonate 5-lipoxygenase inhibitor | INHIBITOR | https://conductscience.org/library/genes/240 |
Source ChEMBL
Diseases11
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| asthma | Approval | DailyMed and TTD | 10 | 6 | https://conductscience.org/library/drugs?q=MONDO_0004979 |
| chronic myeloid leukemia | Phase 1 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0011996 |
| Hermansky-Pudlak syndrome | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0019312 |
| acne | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0011438 |
| acute lung injury | Early phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0015796 |
| chronic obstructive pulmonary disease | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005002 |
| idiopathic pulmonary fibrosis | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0000768 |
| inflammation | Early phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MP_0001845 |
| non-small cell lung carcinoma | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005233 |
| pulmonary fibrosis | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0002771 |
1 to 10 of 11Source Open Targets
See all 11 diseasesTrials18
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00493974 | Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study) | Phase 3 | 119 | 2010-03-03 | zileuton | Its name | ClinicalTrials.gov |
| NCT01021215 | Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers | Phase 1/2 | 84 | 2015-04-02 | zileuton | Its name | ClinicalTrials.gov |
| NCT02348203 | Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers | Phase 2 | 63 | 2020-03-23 | zileuton | Its name | ClinicalTrials.gov |
| NCT01805687 | Single Dose Bronchodilatory Study in Asthma | Phase 4 | 25 | 2014-08-18 | zileuton | Its name | ClinicalTrials.gov |
| NCT00723021 | PF-04191834 Single Dose Bronchodilatory Study In Asthma. | Phase 2 | 15 | 2013-02-01 | zileuton | Its name | ClinicalTrials.gov |
| NCT00467831 | Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome | Phase 1/2 | 3 | 2013-08-02 | zileuton | Its name | ClinicalTrials.gov |
| NCT00486343 | Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS | Phase 4 | 400 | zileuton | Its name | ClinicalTrials.gov | |
| NCT00070486 | Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer | Phase 2 | 140 | zileuton | Its name | ClinicalTrials.gov | |
| NCT00098358 | Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris | Phase 2 | 90 | zileuton | Its name | ClinicalTrials.gov | |
| NCT00299065 | Safety Study of Zileuton Injection in Patients With Asthma | Phase 1/2 | 60 | zileuton | Its name | ClinicalTrials.gov |
1 to 10 of 18
See all 18 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Zileuton vs Placebo: serious adverse events | 17 of 60 | 20 of 59 | 119 | NCT00493974 | Trial comparisons |
| Arm I: Zileuton vs Arm II: Zileuton and Celecoxib: serious adverse events | 0 of 60 | 0 of 20 | 80 | NCT01021215 | Trial comparisons |
| Arm I (Aspirin, Zileuton) vs Arm II (Double Placebo): Number of Participants Experiencing Possibly/Probably/Definitely-related Adverse Events | 9 of 31 | 8 of 32 | 63 | NCT02348203 | Trial comparisons |
| Arm I (Aspirin, Zileuton) vs Arm II (Double Placebo): deaths from any cause | 0 of 31 | 0 of 32 | 63 | NCT02348203 | Trial comparisons |
| Arm I (Aspirin, Zileuton) vs Arm II (Double Placebo): serious adverse events | 0 of 31 | 0 of 32 | 63 | NCT02348203 | Trial comparisons |
Papers from its trials6
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL93
GET https://conductscience.org/api/drugs/v1/CHEMBL93/targets